ABBV · 8-K · 20260622PR076067

Product / Drug Pipeline Progress

AbbVie Inc. · 2026-06-22 · Importance 23 · Surprise 24

Apogee’s lead asset, zumilokibart (APG777), is a late-stage, half-life-extended monoclonal antibody targeting IL-13 for atopic dermatitis (AD) and asthma. In a Phase 2 AD trial, approximately two-thirds of treated patients achieved significant skin clearance at 16 weeks, with improvements in itch reduction and overall disease control. Longer-term data supported quarterly or twice-yearly maintenance dosing, addressing convenience and treatment penetration opportunities in AD. APG273 combines zumilokibart with APG333, an anti-TSLP antibody, and Phase 1 data showed APG333 suppressed relevant type 2 inflammatory markers for up to six months after dosing; positive interim asthma data support quarterly or twice-yearly injections for the combination.

Key facts

• Apogee's lead asset is zumilokibart (APG777), a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis. source
• Apogee’s pipeline includes APG273, a combination of zumilokibart and APG333, being developed in asthma. source
• APG333 has Phase 1 data showing a long half-life and was able to suppress relevant type 2 inflammatory markers for up to six months after dosing. source
• Phase 1b interim results of zumilokibart in asthma were positive. source
• In its Phase 2 clinical trial, zumilokibart attained clinically significant results, with approximately two-thirds of patients on treatment achieving significant skin clearance at 16 weeks. source
• Longer-term data from the same trial supports maintenance regimens of either quarterly or twice a year dosing for zumilokibart. source
• Zumilokibart demonstrated notable improvements in itch reduction and overall disease control in the Phase 2 trial. source
• APG273 combination has potential for quarterly or twice-yearly injections in asthma based on Phase 1 and Phase 1b data. source